Epidemiology and clinical impact of EGFR mutation in patients with lung cancer after radical surgical treatment.

Authors

null

Maciej Bryl

E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland

Maciej Bryl , Magdalena Sielewicz , Bartłomiej Budny , Aldona Woźniak , Piotr Gabryel , Mariusz Kasprzyk , Aleksander Barinow-Wojewodzki , Cezary Piwkowski

Organizations

E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland, Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland, Departament of Clinical Patomorphology, Poznań University of Medical Sciences, Poznan, Poland

Research Funding

No funding received

Background: The epidemiology of epidermal growth factor receptor (EGFR) mutation in lung adenocarcinoma and its clinical impact are well-known. However, most studies have focused on advanced-stage inoperable cancer. Data on the frequency of EGFR mutation in surgically resected lung cancer are limited. Recent studies have shown a promising effect of Osimertinib in adjuvant settings. Hence, the need to estimate the target population in the real-world data. This study aimed to assess the occurrence of EGFR mutation in patients after radical surgical treatment of lung adenocarcinoma and explore its prognostic impact compared to EGFR negative group. Methods: This single-center retrospective analysis included the group of 732 consecutive Caucasian patients with histopathologically confirmed lung adenocarcinoma, evaluated for EGFR mutations expression, who underwent anatomical resection between January 2016, and December 2020. EGFR status was assessed by cobas EGFR mutation test v2. The frequency of EGFR mutations, disease-free survival (DFS) and overall survival (OS) in EGFR positive and EGFR negative groups were analyzed. Results: EGFR mutations were found in 65 surgical patients (8.9%) and did not differ from patients with advanced stages of lung adenocarcinoma (7.9%). EGFR mutations occurred more frequently in females than males, 48 out of 344 (14%) and 17 out of 388 (4.4%), respectively. Deletions within exon 19 and the L858R mutation in exon 21 constituted 49.2% and 24.6% of all mutations, respectively, while others comprised 26.2%. One case of L858R mutation coincided with T790M in exon 20 mutation. Detailed results divided by stages are presented in the Table. The occurrence of EGFR mutation had no significant influence on DFS and OS in patients after radical resection. Conclusions: The frequency of EGFR mutation in postoperative lung cancer was comparable to the occurrence in the general lung cancer population. EGFR mutation did not affect DFS and OS in patients after radical resection.

Summary of the EGFR mutation results by stage.

Stage1
EGFR mutation-positive patients [n (%)]
Total numer of patients
IA
12 (7.3)
165
IB
20 (10.2)
196
IIA
5 (10.9)
46
IIB
8 (5.9)
136
IIIA
16 (10.8)
148
IIIB
4 (9.8)
41

1According to the 8th edition of IASLC guidelines.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8552)

DOI

10.1200/JCO.2022.40.16_suppl.8552

Abstract #

8552

Poster Bd #

179

Abstract Disclosures

Similar Abstracts

First Author: Jonathan N. Priantti

First Author: N/a Zhoutong

First Author: Fang Wu

Abstract

2022 ASCO Annual Meeting

The impact of EGFR Exon 20 mutation subtypes on lung cancer prognosis.

First Author: Ming Xu